Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Researchers confirmed that black-legged ticks (Ixodes scapularis) can trigger alpha-gal syndrome in humans. A 10-year ...

The biosimilar was not approved for other forms of urticaria, nor for acute or emergency ... fracture, arm pain, pruritus, dermatitis, and earache were reported in at least 1% of patients.

Polymorphous appearance, including pruritus, erythema, edema, vesicles, or necrosis. Usually restricted to areas of skin contact. Contact urticaria, (nonimmunologic) Seconds to minutes Minutes to ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries ...

Select secondary endpoints evaluated at 36 weeks included: Proportion of patients achieving ≥90% reduction in Bullous Pemphigoid Disease Area Index (scale: 0-360) Proportion of patients with ≥4-point ...

and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the EU. About COPD COPD is a ...